AzTrials
AzTrials

Transplant DysfunctionNCT04643665

Prediction of Pulmonary Graft Dysfunction After Double-lung Transplantation (PGD3-AI Study)

An observational study of Transplant Dysfunction and Transplantation, Lung, run by Hopital Foch.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The thundering evolution of lung transplantation management during the past ten years and primary graft dysfunction (PGD) new definition have led to new predictive factors of PGD. Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Transplant Dysfunction, Transplantation, Lung
What is being tested?
Double-lung transplantation
Type of treatment
Surgery or procedure
How many people
478 participants
Where
No sites listed yet
Study dates
1 Jan 2012to 5 Oct 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Lung transplanted patients

Who may be able to join

  • double-lung transplantation

Who cannot join

  • multi-organ transplant
  • use of a cardiopulmonary bypass
  • repeated transplantation during the study period for the same patient.

About this study

Official title: Prediction of Grade 3 Pulmonary Graft Dysfunction After Double-lung Transplantation From Donor, Recipient and Intraoperative Variables

The thundering evolution of lung transplantation management during the past ten years and primary graft dysfunction (PGD) new definition have led to new predictive factors of PGD. Therefore, we retrospectively analyzed a monocentric database using a machine-learning method, to determine the predictive factors of grade 3 PGD (PGD3), defined as a PaO2/FiO2 ratio < 200 or being under extracorporeal membrane oxygenation (ECMO) at postoperative day 3.

We included all double lung transplantation from 2012 to 2019 and excluded multi-organ transplant, cardiopulmonary bypass, or repeated transplantation during the study period for the same patient. Recipient, donor and intraoperative data were added in a gradient boosting algorithm step-by-step according to standard transplantation stages. Dataset will be split randomly as 80% training set and 20% testing set. Relationship between predictive factors and PGD3 will be represented as ShHapley Additive exPlanation (SHAP) values.

Read the detailed description

The standardized anesthetic management has been previously described 18 and is detailed on the web site http://anesthesie-foch.org/protocoles-anesthesie/ ("The Foch lung transplant anesthesia protocol").

Continuous variables are presented as median + interquartile range (IQR) or mean and 95%CI, and were compared using independent T-test or Mann-Whitney test. Categorical variables are presented as n (%) and were compared using Chi-squared test or Fisher's exact test. We applied machine learning algorithm to predict 3-day ahead primary graft dysfunction after lung transplant surgery among patients. Machine learning is a branch of artificial intelligence where computer systems can learn from available data and identify patterns with minimal human intervention. Machine learning algorithm tests on data and performance metrics were used to obtain the higher performing algorithm. In this study, we performed a XGBoost (Gradient Boosting) algorithm which was a combination of decisions trees. Each decision tree typically learned from its precursor and passed on the improved function to the following. The weighted combination of these trees provided the prediction.

No particular data transformation has been performed on numerical variables. Categorical variables have been encoded as integer, without any further pre-processing steps. In particular, no specific processing has been performed to deal with missing data. The default behavior of XGBoost has been used. It consists in treating missing data as a specific modality. During the training step of XGBoost models, missing values are treated as other values, and left or right decisions at any branch of a tree are learned by optimizing the outcome.

In order to reflect the sequential nature of this predictive medicine problem, nine steps have been defined to take into account incrementally observed variables acquired at various stages of the surgery.

Step 1: recipient variables Step 2: donor variables Step 3: arrival in the OR Step 4: after anesthetic induction Step 5: during first pneumonectomy Step 6: after first graft implantation Step 7: second pneumonectomy Step 8: second graft implantation Step 9: end surgery status At each of the nine steps, a cross-validation procedure is employed to assess the predictive performance of a machine learning model (XGBoost). One repetition of the cross-validation procedure is designed as follows: the dataset of subjects is randomly split into eight disjoint parts. Successively, the performance of the XGBoost model on each of the eight subset,while training the machine learning model using the remaining seven subsets. For such a repetition, the predictive probability of 3-day ahead primary graft dysfunction for each subject is retained to finally compute the area under ROC (receiving operator curve). To evaluate the variability of the predictive performance of the machine learning model, this cross-validation procedure is repeated fifty times, with randomly chosen subjects partitions. For each of the fifty times eight times nine (repetitions, partitions, surgical steps), hence 3600 models training, a conservative approach has been adopted for XGBoost training, consisting in a unique set of training parameters. These parameters have been chosen to prevent overfitting due to a relatively small number of subjects compared to the number of variables, especially categorical variables, which yield a high degree of freedom. Specifically XGBoost has been trained for 400 rounds (no early stopping), a maximum depth of 5 for each tree, a minimum child weight of 3, and a learning parameter eta equals to 0.0002. Besides those conservative parameters chosen to prevent overfitting, only 40 percents of available columns are selected for tree construction at each round, and 95 % of subjects. These parameters have been kept fixed and chosen to ensure stability of results. Small perturbations around these values could result in local performance improvements, but would not be practically chosen given the size of the dataset.

In order to gain some insights into the most useful variables in terms of predictive power, we then conducted a post-hoc analysis based on the following methodology: at each surgical step, 400 models have been trained for the repeated cross-validation procedure. For each model, we retain the rank of each variable as given by the variable importance procedure of XGBoost. The average rank of each variable for each step is then computed by averaging the ranks obtained by variables for each of the 400 models. At step 9, variables are ordered based on their average rank (increasing average ranks). They are then incrementally used as input of a new cross-validation procedure (repeated 20 times).

Being tested
Double-lung transplantation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Double-lung transplantationProcedure or surgery

Study groups in NCT04643665
Study groupRoleWhat they receive
No grade 3 Pulmonary graft dysfunction at postoperative day 3patients having not a grade 3 Pulmonary graft dysfunction at postoperative day 3
Receives: Procedure: Double-lung transplantation
Grade 3 Pulmonary graft dysfunction at postoperative day 3patients having a grade 3 Pulmonary graft dysfunction at postoperative day 3
Receives: Procedure: Double-lung transplantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. risk factors for grade 3 pulmonary graft dysfunction at postoperative day 3

    PaO2/FiO2 ratio < 200 or being under extracorporeal membrane oxygenation (ECMO) at postoperative day 3 due to hypoxemia

    Measured: 3 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2020
  2. Study start1 Jan 2012
  3. Primary completion31 Dec 2019
  4. Study completion5 Oct 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
478 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04643665
Sponsor's protocol ID
1111111111111
Status last verified
Nov 2020
First submitted
19 Nov 2020
Last updated
25 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Transplant Dysfunction and Transplantation, Lung, run by Hopital Foch.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

risk factors for grade 3 pulmonary graft dysfunction at postoperative day 3 (time frame: 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in